Streetwise Reports' Article Archives — March 2024 back to current month (13)
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
AI Co. Funded To Develop AI Approach to Health Equity (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
AI Medical App Passes Standard Student Test (03/26/2024)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.
Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says (03/26/2024)
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.
Biotech Co.'s Target Price Significantly Higher Than Current (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Biotech Stocks Break Out (03/19/2024)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
Is This Pharma Set To Break Out After COPD Drug Approval? (03/15/2024)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
This Biotech Is a Potential Disruptor, Expert Says (03/12/2024)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say (03/12/2024)
The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating.
Safe Supply Firm Announces Another Promising Acquisition (03/11/2024)
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector.
Healthcare AI Firm Has 'Bright Future,' Analyst Predicts (03/08/2024)
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.
NY Biotech Has Potentially Game Changing Anxiety Therapy (03/07/2024)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
Bionic Medical Co. Has Sufficient Funds to Operate Through 2024 (03/05/2024)
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
